ERBB2 and cancer: With an 8:1 ratio of CAR-T cells to target cells, anti-HER2 CAR-T cells exhibited over 80% cytotoxicity against all tested cancer cell lines, regardless of their HER2 expression status, indicating potential off-target effects.